JCR Pharmaceuticals Co Ltd 2023 Integrated Report
The report describes FY2022 revenue and profit declines following the end of COVID-19 vaccine stock-solution manufacturing, while highlighting continued growth through rare-disease development, J-Brain Cargo technology, and global partnerships. It sets out the Reach Beyond, Together midterm plan for FY2023-2027 and its focus on R&D, manufacturing, quality assurance, and human-resource development. Sustainability governance was strengthened through new advisory, sustainability, and environmental committees, alongside a materiality process and TCFD-aligned climate disclosure. The report also quantifies Scope 1, Scope 2, and partial Scope 3 emissions for FY2022.
Company: JCR Pharmaceuticals Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2023
Type: Integrated Report
Pages: 96
Back to company
JCR Pharmaceuticals Co Ltd
Jcr Report
The report describes FY2022 revenue and profit declines following the end of COVID-19 vaccine stock-solution manufacturing, while highlighting continued growth through rare-disease development, J-Brain Cargo technology, and global partnerships. It sets out the Reach Beyond, Together midterm plan for FY2023-2027 and its focus on R&D, manufacturing, quality assurance, and human-resource development. Sustainability governance was strengthened through new advisory, sustainability, and environmental committees, alongside a materiality process and TCFD-aligned climate disclosure. The report also quantifies Scope 1, Scope 2, and partial Scope 3 emissions for FY2022.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Apr 1, 2022 - Mar 31, 2023
Fiscal Year
2022
Published
Nov 1, 2023
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Women in Management
Employees